Amgen's Vectibix hits PhIII survival goal in previously treated mCRC patients

Amgen's ($AMGN) Vectibix already has an FDA nod for first-line treatment of wild-type KRAS metastatic colorectal cancer. And now, new data show, it's hit its goals in previously treated patients, too. The treatment trumped best supportive care in patients who had failed to respond to chemo, posting a statistically significant improvement in overall survival to nail the primary endpoint of a Phase III study. Release | More